Nyxoah's Genio System Shows Strong Efficacy in Complete Concentric Collapse Patients
Event summary
- Nyxoah presented full 12-month data from the ACCCESS U.S. pivotal study at ISSS 2026, showing a 74.3% median reduction in AHI with Genio® bilateral stimulation in Complete Concentric Collapse (CCC) patients.
- The study met both co-primary efficacy endpoints: 77.2% AHI responder rate and 87.7% ODI responder rate, with no device- or procedure-related serious adverse events.
- Nyxoah submitted a PMA supplement to the FDA to expand Genio’s indication to CCC patients, a population with no commercially available neurostimulation option in the U.S.
- Patients reported significant improvements in quality of life, with 94.7% reporting improvement and 97.4% satisfied with the implant.
The big picture
Nyxoah’s positive 12-month data from the ACCCESS study positions Genio as a potential game-changer for OSA patients with Complete Concentric Collapse, a population currently underserved in the U.S. The submission of a PMA supplement to the FDA marks a critical step in expanding Genio’s market reach, potentially tapping into a significant unmet clinical need. The company’s ability to deliver on this opportunity will hinge on regulatory approval and subsequent market adoption.
What we're watching
- Regulatory Approval
- Whether the FDA will approve the PMA supplement, allowing Nyxoah to expand Genio’s indication to CCC patients in the U.S.
- Market Expansion
- The pace at which Nyxoah can penetrate the U.S. market with Genio, given the unmet need for neurostimulation options in CCC patients.
- Clinical Outcomes
- How long-term follow-up data from the ACCCESS study will impact Genio’s adoption and reimbursement landscape.
